(Q38648370)

5 September 2017

1 reference

title

Results of long-term subcutaneous desferrioxamine therapy (English)

1 reference

5 September 2017

1 reference

Hoffbrand AV

1

1 reference

5 September 2017

Wonke B

series ordinal

2

1 reference

5 September 2017

publication date

1 April 1989

1 reference

Best Practice and Research: Clinical Haematology

5 September 2017

published in

1 reference

5 September 2017

volume

2

1 reference

5 September 2017

issue

2

1 reference

5 September 2017

page(s)

345-362

1 reference

Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Combined vitamin D parathyroid defect in thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Long-term Chelation Therapy in Thalassaemia Major: Effect on Liver Iron Concentration, Liver Histology, and Clinical Progress

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Growth and sexual maturation in thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Depletion of excessive liver iron stores with desferrioxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Insulin Resistance and Iron Overload

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Serum 1,25 dihydroxyvitamin D and osteocalcin concentrations in thalassaemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

The development of diabetes mellitus and chronic liver disease in long term chelated beta thalassaemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Induction of spermatogenesis in thalassaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Insulin dependent diabetes in thalassaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Serum ferritin, liver iron stores, and liver histology in children with thalassaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Early iron overload in beta-thalassaemia major: when to start chelation therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Early left ventricular dysfunction and chelation therapy in thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Hypogonadism in hemochromatosis: reversal with iron depletion

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Gonadotrophin, thyrotrophin and prolactin reserve in beta thalassaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Congestive cardiomyopathy and haemochromatosis--rapid progression possibly accelerated by excessive ingestion of ascorbic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Growth retardation, skeletal maturation and thyroid function in children with homozygous beta-thalassaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Transfusional iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Endocrine Functioning in Multitransfused Prepubertal Patients with Homozygous β-Thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Survival and desferrioxamine in thalassaemia major.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

1 reference

7 January 2021

Continuous subcutaenous administration of deferoxamine in patients with iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Iron overload associated with congenital pyruvate kinase deficiency and high dose ascorbic acid ingestion

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Primary hypothyroidism and the low T3 syndrome in thalassaemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Clinical consequences of acquired transfusional iron overload in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Hypogonadotropic hypogonadism in hemochromatosis: recovery of reproductive function after iron depletion

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Adrenal function in thalassemia major following long-term treatment with multiple transfusions and chelation therapy. Evidence for dissociation of cortisol and adrenal androgen secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

Serum 25-hydroxyvitamin D levels in thalassaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980021-6

7 January 2021

10.1016/S0950-3536(89)80021-6

Identifiers

DOI

1 reference

5 September 2017

1 reference